4.4 Article

Attributable mortality of nosocomial Acinetobacter Bacteremia

期刊

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
卷 28, 期 3, 页码 293-298

出版社

UNIV CHICAGO PRESS
DOI: 10.1086/512629

关键词

-

向作者/读者索取更多资源

OBJECTIVE. To determine the attributable mortality and outcome of nosocomial Acinetobacter bacteremia. DESIGN. Matched, retrospective cohort study. SETTING. Large, university- based, tertiary care center. PATIENTS. Of 219 patients with nosocomial Acinetobacter bacteremia identified by prospective surveillance during a 3- year period, 52 met the criteria for the study and were matched to a control patient by age, sex, primary and secondary diagnosis, operative procedures, and date of admission. RESULTS. A 100% success rate was achieved in the proportion of case patients and control patients matched for the compared criteria, except for major operative procedures ( 88%) and the presence of an important secondary underlying disease ( 54.5%). Twenty- nine ( 55.7%) of the case patients died, compared with 10 ( 19.2%) of the control patients (). The attributable mortality was 36.5% ( 95% CI, 27%- 46%) and the risk ratio for death was 2.9 ( 95% CI, 1.58- 5.32). In a multivariate survival analysis, older age, mechanical ventilation, renal failure, and Acinetobacter bacteremia ( hazard ratio [ HR], 4.41; 95% confidence interval [ CI], 1.97- 9.87; P<.001) were found to be independent predictors of mortality. There was a trend for a longer median duration of hospitalization among case patients, compared with control patients ( 11.5 vs. 6.5 days; Pp=.06). Three isolates were resistant to all but 1 antibiotic tested ( colistin), and 45 isolates ( 86.5%) were resistant to 4 or more different antibiotic classes. CONCLUSIONS. When adjusted for risk- exposure time and severity of disease at admission, nosocomial Acinetobacter bacteremia is associated with mortality in excess of that caused by the underlying diseases alone.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据